ISRG vs ROK: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

ISRG is the larger of the two ($154.51B market cap): the incumbent the market prices for continued execution (35.75x forward earnings, beta 1.44). ROK is the smaller challenger ($43.69B), cheaper on forward earnings (23.57x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.

ISRG vs ROK: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricISRGROKWhat it tells you
Market cap$154.51B$43.69BSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E35.7523.57Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Trailing P/E53.9031.37Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price.
Beta1.441.51Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range43% of range31% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.
Price / book9.6612.30How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price.

Reading it: ROK is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

Before you buy: how ISRG and ROK affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ISRG and ROK share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ISRG and ROK exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does Intuitive Surgical (ISRG) do?

Intuitive Surgical (ISRG) is the dominant maker of robotic-assisted surgery systems, best known for the da Vinci platform used in minimally invasive procedures across urology, gynecology, general surgery, and other specialties. Its business model is razor-and-blade: Intuitive sells or places the large capital systems, then earns high-margin recurring revenue from the single-use instruments and accessories consumed in each procedure, plus service contracts. As the installed base of systems grows and procedure volumes rise, recurring revenue compounds. The company has expanded its platform with newer systems (including the da Vinci 5 and the Ion platform for lung biopsy), and benefits from surgeon training, hospital workflow integration, and a large library of validated procedures that create high switching costs. Intuitive went public in 2000 and is headquartered in Sunnyvale, California.

Full ISRG guide

What does Rockwell Automation (ROK) do?

Rockwell Automation (ROK) is one of the largest pure-play industrial automation and digital transformation companies in the world. It provides the hardware, software, and services that factories and industrial facilities use to run, monitor, and optimize their operations: programmable logic controllers, drives, motor control, sensors, industrial networking, and the Allen-Bradley and FactoryTalk product families that are standards in many North American plants. Rockwell organizes its business around Intelligent Devices, Software and Control, and Lifecycle Services, and increasingly pairs its installed base of automation hardware with software, analytics, and recurring services. A long partnership with software firms and its acquisitions in areas like manufacturing-execution software, cybersecurity, and information solutions position it to sell connected, data-driven factory systems, not just discrete controllers. Founded in 1903 and headquartered in Milwaukee, Wisconsin, Rockwell is an S&P 500 industrial that benefits from secular trends in reshoring, factory modernization, and the digitization of manufacturing, while remaining tied to the capital-spending cycles of its industrial customers.

Full ROK guide

ISRG vs ROK: how do they differ?

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

  • ISRG drivers: Razor-and-blade recurring revenue; Installed base and switching costs.
  • ROK drivers: Installed base and switching costs; Software, recurring revenue, and analytics.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: ISRG trades at a premium valuation (about 49 times trailing earnings and 14 times sales as of October 2026), so any slowdown in procedure growth, system placements, or margins can compress the multiple sharply; the stock's 24% decline in 2026 despite double-digit growth shows how that can play out. For ROK, rockwell's results are tied to industrial and manufacturing capital-spending cycles, so demand can soften in downturns or when customers delay projects, and orders can be lumpy.

ISRG or ROK: which should you pick?

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick ISRG if you believe its drivers more; ROK if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ISRG and ROK guides.

ISRG vs ROK: the full fundamentals

ISRG. At about $429 on October 16, 2026, Intuitive trades near 49 times trailing earnings and 35 times forward earnings, cheaper than at the start of the year after a 24% share-price decline while earnings kept growing about 26%. The premium is still the central debate: bulls point to the durability of the razor-and-blade model and four straight earnings beats, while bears point to multiple-compression risk if procedure growth slows or Medtronic and J&J gain share. Q3 2026 results on October 20 carry a consensus of about $2.64 EPS on $2.91 billion of revenue.

ROK. Rockwell trades at a premium multiple relative to the broader industrials group, a gap explained by its pure-play automation focus, strong installed-base moat, and growing software mix: ~40 times trailing GAAP earnings, ~29 times forward estimates and ~24 times EV/EBITDA as of October 16, 2026. The trailing multiple overstates the premium because GAAP earnings are still recovering from fiscal 2025; on analysts' fiscal 2027 estimate of ~$14.92 the stock is near 29 times. The 25 analysts tracked carry a mean target near $476, and the fiscal fourth-quarter report expected around November 5, 2026 is the next catalyst for the multiple.

Headline figures (approximate, October 2026): ISRG shows revenue (ttm) ~$11.0B, q2 2026 revenue growth ~18.5% YoY, gross / operating margin ~67% / ~34%, net income (ttm) ~$3.1B (EPS ~$8.72); ROK shows revenue (ttm) ~$8.97 billion (June 2026 quarter up ~8% year over year), margins (ttm) ~49% gross, ~21% operating, ~13% net, net income (ttm) ~$1.2 billion; trailing EPS ~$10.68, adjusted eps, june 2026 quarter $3.49 vs ~$3.38 consensus.

The bottom line: ISRG vs ROK

ISRG and ROK are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined ISRG and ROK exposure against your real portfolio. It is not an investment adviser.

Wondering how ISRG or ROK fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Intuitive Surgical

Ask Walnut's AI anything about ISRG and see how it fits what you own.

FAQ

What is the difference between ISRG and ROK?

+

Intuitive Surgical (ISRG) is the dominant maker of robotic-assisted surgery systems, best known for the da Vinci platform used in minimally invasive procedures across urology, gynecology, general surgery, and other specialties. Rockwell Automation (ROK) is one of the largest pure-play industrial automation and digital transformation companies in the world. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is ISRG or ROK the better stock?

+

Neither is universally better. ISRG is the larger incumbent; ROK is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, ISRG or ROK?

+

On forward P/E (as of November 2026), ISRG trades at 35.75x and ROK at 23.57x, so ROK is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both ISRG and ROK?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of ISRG vs ROK?

+

ISRG: ISRG trades at a premium valuation (about 49 times trailing earnings and 14 times sales as of October 2026), so any slowdown in procedure growth, system placements, or margins can compress the multiple sharply; the stock's 24% decline in 2026 despite double-digit growth shows how that can play out. Competition is intensifying as Medtronic (Hugo), Johnson & Johnson and others bring rival surgical-robotics platforms to market, and October 2026 commentary has focused on new robotics competition. Hospital capital budgets are cyclical and can defer system purchases in tight economic periods. Reimbursement changes, regulatory scrutiny of new systems, and any safety or recall issues are risks. The company is also exposed to global healthcare-spending trends, tariffs and currency, and the high valuation leaves little room for execution missteps. ROK: Rockwell's results are tied to industrial and manufacturing capital-spending cycles, so demand can soften in downturns or when customers delay projects, and orders can be lumpy. It competes with large global automation rivals like Siemens, Schneider Electric, ABB, and Emerson, several of which have broader geographic and product breadth. Exposure to specific end markets (autos, semiconductors, food and beverage, energy) introduces concentration and cyclicality. Supply-chain disruptions and component availability have affected lead times in the past. The stock often trades at a premium multiple for an industrial, so disappointing orders or margins can pressure the valuation. Valuation is the near-term pressure point: at ~40 times trailing and ~29 times forward earnings in mid-October 2026, the stock sits below several recently trimmed analyst targets (Morgan Stanley cut its target to $520 from $545 and Mizuho to $430 from $445), and it has fallen ~8% over three months. Debt of ~$3.6 billion against ~$479 million of cash is manageable but higher than the company carried before recent acquisitions.

Related comparisons

Browse all stock comparisons.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell ISRG or ROK; figures are approximate and dated (as of November 2026). Verify current data before investing.